trial
as of 2026-07-01Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
NCTId NCT05656469
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Recruiting
Enrollment
2,500 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2023-02-23
Primary completion
2026-09
Eligibility
ALL · 16 Years · 70 Years
Interventions & indications
Sponsors
Parnassia GroepLead Sponsor
Parnassia Psychiatric InstituteCollaborator
University of BelgradeCollaborator
University of BonnCollaborator
Babes-Bolyai UniversityCollaborator
Ludwig-Maximilians - University of MunichCollaborator
King's College LondonCollaborator
University of BarcelonaCollaborator
Investigators
3
Roos van Westrhenen, Professor (PhD&MD)Principal Investigator
Allan Young, Professor (MD&PhD)Study Chair
Mario Juruena, Professor (MD&PhD)Study Chair
Sites
9 total
Syracuse, United StatesBonn, GermanyMünchen, GermanyAmsterdam, NetherlandsMaastricht, NetherlandsCluj-Napoca, RomaniaBelgrade, SerbiaBarcelona, SpainLondon, United Kingdom
Facts & assertions
4 sourced
Enrollment
2,500
Phase
NA
Primary Completion Date
2026-09
Status
RECRUITING
relationships
The graph out of here
lead_sponsor
company
collaborator
company
indication
investigator